To investigate the leptin and TNF systems in relation to testosterone in insulin resistant myotonic dystrophy (DM1) subjects. DESIGN AND SUBJECTS: Fasting morning samples and diurnal sampling during 24 h. Forty-two DM1 subjects (20 women and 22 men; age 41.5 (28.5 -58.7) y, body mass index (BMI) 23.3 (18.6 -29.2) kg=m 2 ; median and 10th and 90th percentile, respectively). Fifty healthy volunteers (23 women and 27 men; age 42 (27.0 -56.9) y, BMI 24.0 (20.7 -29.7) kg=m 2 ). Nine men with DM1 and nine healthy men participated in diurnal sampling. MEASUREMENTS: Body composition was measured by bioelectric impedance analysis. Circulating levels of leptin, TNF-a, TNFR-II, insulin, testosterone and lipids were measured. The number of CTG triplet repeats was analysed. RESULTS: Basal as well as median 24 h levels of leptin and TNFR-II were significantly increased in DM1 patients, independent of body fat mass. This was associated with higher insulin and lower testosterone levels in DM1 patients. The genetic defect was related to leptin and TNFR-II levels in DM1 patients. CONCLUSION: Hyperleptinemia in DM1 is clearly linked to the concomitant hypogonadism. The genetic defect may directly or indirectly contribute to increased leptin levels. Increased exposure of cytokines may contribute to insulin resistance and other hormonal disturbances in DM1.
Introduction
The metabolic syndrome consists of a cluster of factors, including insulin resistance, impaired glucose tolerance, hypertension, central obesity, and hypertriglyceridemia. 1 Insulin resistance is also a cardinal feature of myotonic dystrophy (DM1); the most common inherited muscular dystrophy in adults. 2 Like other patients with the metabolic syndrome, DM1 patients have an increased body fat mass and increased circulating triglyceride levels. 3 -5 However, glucose intolerance is unusual, and blood pressure is not increased. 2 Furthermore, there is no obvious increase in atherosclerosis or cardiovascular disease in DM1. 2 The metabolic syndrome is associated with disturbed cortisol regulation, impaired fibrinolysis and altered secretion of specific hormones=cytokines including leptin and tumour necrosis factor-a (TNF-a). 6 -8 We have previously shown derangements in cortisol regulation and fibrinolysis in DM1. 9 -11 Furthermore, a baseline hyperleptinaemia has been documented in DM1, 5 but so far the 24 h leptin profile has not been established.
Leptin is mainly produced by adipose tissue, although production also in other tissue, such as the gastric epithelium and in the placenta, has been demonstrated, and circulating levels are closely related to fat mass. 5, 12 Leptin levels show a diurnal rhythm with a nocturnal peak. Besides a close correlation to fat mass, the secretion of leptin has been suggested to be modulated by insulin, glucocorticoids, TNF-a, and testosterone. 13 -15 TNF-a has been attributed an important position in the pathogenesis of insulin resistance. 16, 17 The actions of TNF-a are mediated by two distinct receptors, TNF receptors 1 and 2  (TNFR-I and TNFR-II) . 18 There are soluble forms of both receptors, and TNF-a as well as both receptors are released from adipose tissue. 19 We have previously shown increased levels of 24 h TNF-a in DM1. 10 TNFR-II levels are elevated in obese females, 20 and basal levels of TNFR-II were recently shown to be increased in DM1 patients. 4 Whether levels of TNFR-II are subject to any diurnal fluctuations in DM1 has not been studied.
Furthermore, testosterone has been suggested to be involved in the regulation of leptin, and may contribute to the well-known gender differences in leptin secretion. 21, 22 Importantly, hypogonadism is a well-known feature of men with DM1, and circulating testosterone levels are markedly decreased. 2, 9 To clarify abnormalities in circulating levels of leptin and TNF-a=TNFR-II in insulin resistant DM1 patients, we have examined (i) whether subjects with DM1 display, in conjunction with hyperleptinaemia and the disturbed diurnal cortisol rhythmicity, changes in the diurnal leptin profile; (ii) to what extent testosterone and TNF-a levels are associated with the hyperleptinaemia independent of the increased body fat mass in these patients; and (iii) the diurnal rhythmicity of TNFR-II to explore whether the disturbances in DM1 subjects have a common denominator in a deranged TNF system.
Subjects and methods

Subjects
Forty-two (20 women and 22 men) DM1 subjects were recruited from the 109 DM1 patients registered at the Dystrophia Myotonica (DM) Centre in Boden, northern Sweden, where the prevalence of the disease is exceptionally high. 23 Inclusion in the study was based on medical grounds. All patients included had clinically overt myotonia and muscular dystrophy. The diagnoses were based on genetic analyses. Clinical data of DM1 patients and controls are summarized in Table 1 .
Fifty healthy volunteers (23 women and 27 men), recruited from advertisements in the local newspaper, were used as controls.
Nine of the 22 men with DM1 also volunteered to participate in diurnal sampling. Nine healthy men from the control groups served as controls. The median age of this subgroup of males was for DM1 patients 41 AE 4.0 (21 -60) y (median AE s.e.; min -max) and for controls 39 AE 4.6 (21 -60) y. Median body mass index (BMI) of the patients was 24.9 AE 1.0 (median AE s.e.) and of the controls 23.1 AE 0.9 (median AE s.e.).
None of the patients or controls were on any relevant medication, had clinical or laboratory signs of endocrinological dysfunction (including diabetes mellitus and thyroid disease), cardiac failure, renal or hepatic insufficiency, infection or inflammation, and none was hospitalized at the time of the study. Furthermore, none of the patients or controls had a diagnosis or any symptoms of sleep apnoea.
This study was approved by the regional ethical committee, and all participants had given their informed consent to participate in these studies.
Sampling and measurements
Body composition was measured in all participants by bioelectrical impedance analysis (Akern-RJL Systems BIA 101, EL-DOT K=S, Fredriksvaerk, Denmark). The BIA failed to measure four patients due to too high resistance.
Blood samples were collected at 07:00 and analysed for leptin, TNF-a, TNFR-II, insulin, testosterone and blood lipids. In the substudy of diurnal sampling, the patients underwent diurnal sampling at five times, 07:00, 11:00, 16:00, 22:00, and 02:00. These samples were analysed regarding leptin, TNF-a and TNFR-II.
Analytical methods
Serum concentrations of leptin were analysed by radioimmunological methods, using commercial kits obtained from Linco Research Inc., St Louis, MO, USA. Serum concentrations of TNF-a and TNFR-II were determined by an immunoassay from R&D Systems Europe Ltd, Abingdon, UK. Serum testosterone was determined using a commercial radioimmunoassay kit (Diagnostic Products Corp., Los Angeles, CA, USA). Serum insulin concentrations were analysed by an immunoassay from Abbott Diagnostics, Abbott Park, IL, USA. Serum total cholesterol, HDL cholesterol and triglycerides were determined by routine methods on multianalyser Vitros 950 IRC (Johnson & Johnson, Clinical Diagnostics Inc., NY, USA). LDL cholesterol levels were calculated using the Friedenwald formula.
Detection limits and total coefficients of variation were for serum leptin 0.2 mg=l and 3%, serum TNF-a 4.4 ng=l and 4%, serum TNFR-II 1.0 ng=l and 6%, serum testosterone 0.2 nmol=l and 11%, serum triglycerides 0.11 mmol=l and 1.3%, serum total cholesterol 1.29 mmol=l and 0.9%, serum insulin 1.0 mU=l and 4.4%.
Genetic analyses
Genomic DNA was prepared from blood collected in EDTAtubes according to standard procedures and digested with EcoRI or PstI according to manufacturer's instructions. Southern blotting and hybridizations were performed according to standard. 24 The probe used was pM10M6, 25 a 1.4 kb fragment that flanks the expanded region of the Myotonic Dystrophy Protein Kinase gene. The allele sizes were calculated with the computer program DNAfrag version 3.03.
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Statistical analyses
All statistics were performed using a commercial computer program, SPSS 1 . We used Spearman's rank correlation test for correlation analyses and Mann -Whitney U-test exact Pvalue for comparisons between groups. We also used partial rank correlation analyses, when correlations between two variables were controlled for the influence of a third variable. The models of the partial rank correlations used are described in the Results section.
In cases where the hormone level was below the detection limit, the value was set to half the detection limit for statistical calculations. A P-value of < 0.05 was considered significant.
Results
TNF-a, TNFR-II and leptin
Basal levels of leptin and TNFR-II were significantly increased in DM1 patients whereas there was no significant difference in TNF-a levels ( Table 1) . After adjustment for body fat mass, leptin levels were still increased (Table 1) , indicating an increased secretion of leptin from adipose tissue.
In univariate Spearman analysis, TNF-a levels correlated to TNFR-II levels in DM1 patients (r s ¼ 0.35; P < 0.05), and this correlation also persisted after adjustment for body fat mass in a partial rank correlation analyses (r s ¼ 0.46; P ¼ 0.01). In contrast, TNF-a or TNFR-II levels did not correlate to leptin (r s ¼ 0.15 and r s ¼ 0.17 in Spearman analysis, respectively). In controls, there were no correlations between leptin, TNF-a, or TNFR-II (r s ¼ 7 0.08 to 7 0.19). Leptin levels correlated to insulin levels in both patients and controls (r s ¼ 0.32; P < 0.05 and r s ¼ 0.40 in Spearman analyses; P < 0.01). However, these correlations were no longer significant after adjustment for body fat mass in a partial correlation analysis (r s ¼ 0.11 -0.15). Univariate Spearman correlations to other hormones and BMI, body fat mass and WHR are shown by gender in Table 2 . In summary, leptin correlated to BMI in both controls and DM1, whereas a negative association between leptin and testosterone was evident only in male DM1 patients.
Diurnal rhythmicity
Diurnal rhythmicity of leptin, TNF-a, and TNFR-II in nine men with DM1 and nine healthy men is illustrated in Figure  1a -c. Patients had increased median 24 h levels of leptin (12.2 (6.8 -20.1) vs 2.7 (2.4 -5.7); P < 0.05; median (25th -75th percentile)), and TNFR-II (2453 (1990 -3547) vs 1809 (1649 -1907); P < 0.01) compared with controls. A nadir in leptin levels at 16:00 was found among DM1 patients but not among controls. Patterns of TNF-a and TNFR-II secretion also differed between groups, albeit less pronouncedly.
Testosterone
Serum testosterone levels were lower in both men and women with DM1 compared to controls of the same gender (Table 1) . In both DM1 patients and controls, there Figure 1 Diurnal circulating levels of (A) serum leptin, (B) serum TNF-a, and (C) serum TNFR-II in nine men with DM1 and nine healthy men. Means AE s.e.m.; are shown. Asterisks indicate a significant probability level of random difference between the two groups, *P < 0.05, **P < 0.01.
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Å Johansson et al were strong negative univariate Spearman correlations between testosterone and leptin (r s ¼ 7 0.43; P < 0.01 and r s ¼ 7 0.66, P < 0.001, respectively). After correction for body fat mass in a partial correlation analysis, this correlation was lost in controls (r s ¼ 7 0.19) but remained significant in DM1 patients (r s ¼ 7 0.55; P < 0.01). In controls, testosterone correlated to body fat mass (r s ¼ 7 0.64; P < 0.001), and waist to hip ratio (WHR) (r s ¼ 0.48; P < 0.001). When separated by gender, testosterone correlated significantly to leptin only in male DM1 patients ( Table 2) .
CTG repeat expansions
Median CTG repeat length in the entire group was 679 (152 -1141; 10th and 90th percentiles). After exclusion of two patients with short CTG repeats but high leptin levels, high CTG repeat number s correlated significantly to increased basal leptin levels (r s ¼ 0.38; P < 0.05). This association persisted after adjustment for body fat mass. In the study of diurnal sampling, median CTG repeat length was 590 (428 -751; 25th and 75th percentiles). The impact of the number of CTG repeats for diurnal levels of leptin and TNFR-II levels is demonstrated in Figure 2a -b. In summary, the number of CTG repeats correlated to leptin levels at 11.00 and 16.00 h (r s ¼ 0.75 and r s ¼ 0.71; P < 0.05 for both) and to body fat mass (r s ¼ 0.83; P < 0.01).
Discussion
This study shows that increased levels of leptin and TNFR-II are present in insulin-resistant patients with DM1. This increase is evident not only in baseline samples taken after an overnight fast but also throughout the 24 h study period. Importantly, leptin levels were elevated independently from body fat mass, suggesting that the regulation of leptin *P < 0.05, **P < 0.01, and ***P < 0.001 compared with men within the same group (controls or DM1). *P < 0.05, **P < 0.01, ***P < 0.001.
Diurnal rhythmicity of leptin, TNF and TNFR-II in DM1 Å Johansson et al production=secretion from adipose tissues is disturbed in DM1 and, consequently, that the hyperleptinaemia is not simply explained by increased adipose tissue mass. Increased leptin levels in DM1 has also been reported by Gó mez et al, 5 and similarly to our study, Gomez et al also showed that the increase in leptin levels in DM1 patients does not correlate to fat mass, which interestingly was different from the increased leptin levels in subjects with type 2 diabetes having identical low insulin sensitivity. 26 Possible explanations for this hyperleptinaemia in DM1 include increased insulin levels since leptin and insulin correlated in bivariate analysis and since insulin is an important stimulator of leptin expression. 12 However, the correlation between insulin and leptin disappeared after correction for body fat mass.
Testosterone has been suggested to inhibit leptin secretion. 27 Our study strongly supports this hypothesis, with a strong negative correlation between testosterone and leptin in DM1 males, independent of body fat mass. The markedly reduced testosterone levels in DM1 patients may thus increase leptin levels through a loss of inhibition in DM1.
Elevated levels of leptin have been suggested as a risk marker for cardiovascular diseases. 7 Our present data seem to contradict this hypothesis, since DM1 patients have a profound insulin resistance without concomitant diabetes, increased blood pressure or increased risk of cardiovascular disease.
2 Furthermore, the possible role of leptin in insulin sensitivity=action is currently not clear. 28 The contribution of hyperleptinaemia to symptomatology in DM1 patients thus remains to be established.
Interestingly, leptin levels correlated to CTG triplet repeat expansions in our patients, indicating a direct or indirect influence of the genetic defect on leptin levels. There is some evidence of a direct genetic effect on the insulin receptor in DM1 since insulin receptor mRNA and insulin protein are decreased in DM1 muscle. 29 Speculatively, the genetic defect may influence leptin receptor and=or function.
TNF-a has been suggested to be important in the pathogenesis of insulin resistance. This seems to be mediated by inhibition of insulin receptor function through its ability to produce serine phosphorylation of insulin receptor substrate-1, decreasing the tyrosine kinase activity of the insulin receptor. 30 Furthermore, TNF-a may influence insulin sensitivity by its actions on leptin production, lipid metabolism, and GLUT-4, 17 although GLUT4 levels have been reported normal in DM1 skeletal muscle cells. 31 In an earlier study, we found increased median 24 h TNF-a levels. However, in the present study this difference was not statistically significant. Possibly, the use of different assays for TNF-a may explain this discrepancy; the assay used in our previous paper 10 measures both free and bound TNF-a, whereas the assay in the present study measures only the free fraction of TNF-a. Therefore, the free fraction of TNF-a seems not to be elevated in DM1.
TNF-a binds two forms of receptors, TNFR-I and TNFR-II, which both appear as membrane-bound and soluble receptors. 18 The TNF receptors have been suggested to represent a Figure 2 Diurnal circulating levels of (A) serum leptin and (B) serum TNFR-II in five men with short CTG repeat expansions and four men with long CTG repeat expansions and in nine healthy men. Means AE s.e.m. are shown. Significant probability levels of random difference are shown as ¼ ¼ for P < 0.01 between subjects with long repeats vs controls, as þ þ for P < 0.05 between subjects with long vs short repeats and as * for P < 0.05 between subjects with short repeats vs controls.
Diurnal rhythmicity of leptin, TNF and TNFR-II in DM1 Å Johansson et al buffer system which would prolong the biologic effects of TNF-a by forming a 'slow release reservoir' and impeding spontaneous denaturation of this cytokine. 32 TNFR-II may inhibit, carry or augment the function of TNF-a. 4 In our DM1 population, we determined TNFR-II and found a clear increase which was seen throughout the 24 h study period, ie in all five samples during the day, complementary to the increase previously demonstrated in DM1 when only one sample was taken. 4 TNFR-I was not determined in the present study. In accordance with our present findings, TNFR-II levels have been reported to be increased in males compared to females. 20, 33, 34 Elevated levels of TNFR-II have also been reported in obesity. 35 In our DM1 population, we found a clear increase in TNFR-II and this was seen throughout the 24 h study period, ie in all five samples during the day, complementary to the increase previously demonstrated in DM1 when only one sample was taken. 4 TNFR-II may play a pivotal role in recruiting TNF-a to specific tissues such as the human adipocyte, thereby inducing insulin resistance. 33 It is therefore of major interest that we found an association between TNFR-II levels and fasting insulin levels as an indirect measure of insulin resistance.
In summary, we have found increased 24-h levels of leptin and TNFR-II in males with DM1, independent of body fat mass. The hyperleptinaemia in DM1 is associated with coexisting hypogonadism and related to the genetic defect. Increased circulating or tissue-specific levels of cytokines can contribute to insulin resistance and other hormonal disturbances in DM1.
